Idenix Pharmaceuticals (IDIX)

[go seek]

JP: So what is the big picture for Idenix...

We are a company that has a new product for hepatitis B treatment that is being launched on a worldwide basis.

We have a "first in class" drug candidate for the treatment of hepatitis C which we believe will have a significant role in any combination therapy for the treatment of hepatitis C.

We have a new 2nd generation non-nucleoside transcriptase inhibitor for HIV treatment in clinical development.

and finally we have a comprehensive discovery program in hepatitis C which we believe should generate at least 3 IND's by year end 2008.

So in addition to this robust anti-viral franchise, we have a supportive strategic partner in Novartis and approximately $162 million in cash.

Source: Q1 2007 Idenix Pharmaceuticals, Inc. Earnings Conference Call.. April 26, 2007